Proteomic Signatures of
Neurodegeneration in Blood

Neurodegenerative diseases impact more than 15% of the global population, and their prevalence is expected to rise dramatically in the coming decades. Yet most diagnoses are made only after irreversible neuronal damage has already occurred, limiting treatment options and outcomes. This white paper explores how high-plex blood-based proteomic profiling reveals critical insights, with potential applications in drug development, clinical trial enrichment and beyond for Alzheimer’s, Parkinson’s and other complex neurological conditions.

Download this white paper to:

• Explore how therapies are moving from symptom relief to targeting root causes
• Discover how blood biomarkers provide early noninvasive insights
• Review case studies highlighting high-plex protein and antibody profiling
• See how integrating proteomics with genomics accelerates causal discovery and validation